Loading…
LifeMD, Inc.
LifeMD, Inc. (LFMD) is listed on NASDAQ and classified in Health Information Services, part of the Healthcare sector. It is headquartered in New York, United States and has 347 employees. The company is worth $112.92M. Revenue was $194.06M in fiscal 2025, up 25.3% from the year before. Net income was $14.35M. The share price is 63.7% below its 52-week high of $6.44. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $4.46M. In that quarter, 3 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -42.5% over 5Y.
today you would have $468.94▼ -53.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 14 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.41 | $4.95 | $8.29 | $1.94 | $3.87 | $6.53 | $0.60 | $0.70 | $1.70 | $1.30 | $0.60 | $0.50 | $1.30 | $0.80 | |
| P/E | — | 13.6x | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NYXHNyxoah SA | $1.11 | — | 1.2x | 0.00% | -122.68% | $113.04M |
| NRXPNRX Pharmaceuticals, Inc. | $2.60 | — | — | 0.00% | — | $112.57M |
| NERVMinerva Neurosciences, Inc. | $2.35 | — | — | 0.00% | — | $112.21M |
| HURATuHURA Biosciences, Inc. | $1.76 |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 2.0x | 0.8x | 1.4x | 2.2x | 0.5x | 1.3x | 4.5x | 0.5x | 0.8x | 3.9x | 1.9x | 3.2x | 4.3x | 9.7x | 6.9x |
| P/B | 25.2x | 7.1x | — | 95.5x | — | 5.2x | — | — | 7.3x | 16.1x | — | 38.4x | — | 40.0x | 34.3x |
| EPS | $0.25 | -$0.60 | -$0.61 | -$1.47 | -$2.25 | -$4.11 | -$0.32 | -$0.14 | -$0.15 | -$0.15 | $0.00 | -$0.10 | -$0.05 | -$0.10 |
| Profit margin | -28.96% | 7.40% | -13.83% | -13.50% | -38.25% | -65.57% | -157.26% | -25.16% | -14.91% | -32.75% | -21.14% | -5.09% | -64.48% | -33.19% | -66.14% |
| ROE | -137.73% | 61.99% | — | -587.56% | — | -267.80% | — | — | -138.22% | -136.74% | — | -61.94% | — | -137.23% | -330.11% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 6.2x |
| 0.00% |
| -161.39% |
| $112.16M |
| ENGNenGene Therapeutics Inc. | $1.67 | — | 0.5x | 0.00% | -60.50% | $111.92M |
| SPRBSpruce Biosciences Inc | $39.65 | — | 1.3x | 0.00% | -105.98% | $113.95M |